Month: January 2023

MINNEAPOLIS, Jan. 04, 2023 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company held its adjourned special meeting of stockholders on January 4, 2023 at 2:00 p.m. (Central Time) (the “Special Meeting”). At the time of the Special Meeting, stockholders (i) approved the Warrant Proposal (as defined below) and (ii) authorized one or more adjournments of the meeting of stockholders to solicit additional proxies in the event there were insufficient votes to approve the Warrant Proposal. A total of 3,815,782 shares of the Company’s common stock were present at the Special Meeting virtually or by proxy, which represents approximately 36% of the shares of common stock outstanding as of the record date for the Special...

Carlsbad, CA, Jan. 04, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering and concurrent private placement with institutional investors for the purchase of 1,052,631 shares of common stock (or certain pre-funded warrants in lieu thereof) at a purchase price per common share of $2.375. Certain investors received unregistered pre-funded warrants in the private placement in lieu of common stock, subject to beneficial ownership limitations. The company has also issued to the investors, in the private placement, unregistered warrants to purchase up to 1,052,631 shares of common stock (the “Common Warrants”). These Common...

• Maximum Potential Dilution of Approximately 23.04%, Based on Share Capital of Cellectis as of September 30, 2022 NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”), pursuant to which it may offer and sell to eligible investors a maximum gross amount of up to $60.0 million of American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis, nominal value €0.05 per share, from time to time in sales deemed to be an “at the market offering” pursuant to the terms of a sales agreement with Jefferies...

SANTA ANA, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Unrivaled Brands, Inc. (OTCQX: UNRV) (“Unrivaled,” “Unrivaled Brands,” or the “Company”), a cannabis company with operations in California, reopens its Blum San Leandro dispensary, spins off two Oregon assets, and names Sabas Carrillo as Chief Executive Officer and as a member of the board of directors, Tracy McCourt as its Chief Revenue Officer, and Jim Miller as its Chief Operating Officer. Operational Updates On December 28, 2022, the Company closed on a Management Services Agreement (the “MSA”) with Brick City Productions, Inc. (the “Operator”) to re-open and fully operate the Company’s San Leandro dispensary, including operations management, inventory management, labor administration, vendor relations, and customer service for a term of 12 months. The Operator is also providing...

Riot Achieves Numerous Key Milestones and Produces All-Time High of 659 Bitcoin in December 2022Riot’s Rockdale Facility The Company is pleased to announce that Building D has reached completion, with the final installation of indoor water cooling frames and completion of electrical testing, and miners deployed. Progress continues in Building E, where Riot’s construction and engineer teams remain focused on the installation of the air-cooling rack system, electrical installation and testing.Riot Platform’s Hash Rate Capacity Growth Graph Updated December 2022 During Q1 2023, Riot anticipates a total self-mining hash rate capacity of 12.5 EH/s, assuming full deployment of approximately 115,450 Antminer ASICs, but excluding any potential incremental productivity gains from the Company’s utilization of 200 MW of immersion-cooling...

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present on January 12, 2023 at 7:30 a.m. Pacific time at the 41st Annual J.P. Morgan Healthcare Conference. A live audio webcast of the presentation will be accessible through Surrozen’s Investor Relations website at investors.surrozen.com. An archived edition of the session will be available later that day. About Surrozen Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential...

NASHVILLE, Tenn., Jan. 04, 2023 (GLOBE NEWSWIRE) — Healthcare Realty Trust Incorporated (NYSE:HR) today announced the completion of $1.14 billion of asset sales and joint venture contributions since July 2022 at a 4.86% cap rate. The Company generated net proceeds of $1.03 billion from these transactions after accounting for HR’s joint venture interest as well as closing-related prorations and capital adjustments. The Company has additional properties under contract to sell for more than $100 million. These additional sales are expected to close by the end of February. The transactions described above include the sale or expected sale of 34 properties and the contribution of 11 properties to joint ventures. Collectively these properties have the following characteristics:49% off-campus 30% single-tenant 12% non-MOB 2.38% average...

NEW YORK, NY, Jan. 04, 2023 (GLOBE NEWSWIRE) — Hudson Acquisition I Corp. (the “Company” or “HUDA”) (Nasdaq: HUDA), today announced that it received written notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with the Nasdaq Listing rule 5250(c)(1) and the matter is now closed. On December 9, 2022, the Company received a standard notice of noncompliance from Nasdaq indicating that, as a result of not having timely filed its quarterly report on Form 10-Q for the period ended September 30, 2022 with the Securities and Exchange Commission, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange...

STEINHAUSEN, Switzerland, Jan. 04, 2023 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) today announced contract awards or extensions for five of its drilling rigs. Together, the fixtures represent approximately $488 million of firm backlog.Deepwater Invictus, an ultra-deepwater drillship, was awarded a new three-well contract with an estimated 100-day duration in the U.S. Gulf of Mexico with an independent operator. The contract contributes an estimated $43 million in backlog and is expected to commence in direct continuation of the rig’s current program. Transocean Barents, a harsh environment semi-submersible, was awarded a new one-well contract with an estimated 110-day duration in the U.K. North Sea with a major operator. The contract contributes an estimated $34 million in backlog and is expected to commence in the first...